Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gordon Mitchell

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
Blood Cancer Journal|September 22, 2021
ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidineNora E Rahmani, Nandini Ramachandra, Srabani Sahu, et al.
Experimental Hematology|February 2, 2026
Pyrimethamine overcomes resistance to hypomethylating agents by reducing de-novo pyrimidine synthesisBianca Rivera-Peña, Samarpana Chakraborty, Yang Shi, et al.
Elife|October 31, 2019
Lactate-mediated epigenetic reprogramming regulates formation of human pancreatic cancer-associated fibroblastsTushar D Bhagat, Dagny Von Ahrens, Meelad Dawlaty, et al.
Cancer Research|June 12, 2016
Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid LeukemiaLohith Bachegowda, Kerry Morrone, Shannon L Winski, et al.
Elife|August 30, 2022
Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutationsGaurav S Choudhary, Andrea Pellagatti, Bogos Agianian, et al.
Leukemia|February 17, 2026
A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemiaSamarpana Chakraborty, Claudia Morganti, Kimberly Zaldana, et al.
Blood|August 15, 2018
North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapiesUrvi A Shah, Elaine Y Chung, Orsi Giricz, et al.
The Journal of Clinical Investigation|September 26, 2018
Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cellsAditi Shastri, Gaurav Choudhary, Margarida Teixeira, et al.
Nature Communications|May 13, 2026
Chromatin rewiring of β-globin and MYC enhancers by TGF-β1 drives defective erythropoiesisSrinivas Aluri, Kimo Bachiashvili, Anjali Budhathoki, et al.
Cancer Discovery|October 1, 2025
Elevated Clonal Hematopoiesis in 9/11 First Responders Has Distinct Age-related Patterns and Relies on IL1RAP for Clonal ExpansionDivij Verma, Rachel Zeig-Owens, David G Goldfarb, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Blood Cancer Journal|September 22, 2021
ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidineNora E Rahmani, Nandini Ramachandra, Srabani Sahu, et al.
Experimental Hematology|February 2, 2026
Pyrimethamine overcomes resistance to hypomethylating agents by reducing de-novo pyrimidine synthesisBianca Rivera-Peña, Samarpana Chakraborty, Yang Shi, et al.
Elife|October 31, 2019
Lactate-mediated epigenetic reprogramming regulates formation of human pancreatic cancer-associated fibroblastsTushar D Bhagat, Dagny Von Ahrens, Meelad Dawlaty, et al.
Cancer Research|June 12, 2016
Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid LeukemiaLohith Bachegowda, Kerry Morrone, Shannon L Winski, et al.
Elife|August 30, 2022
Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutationsGaurav S Choudhary, Andrea Pellagatti, Bogos Agianian, et al.
Leukemia|February 17, 2026
A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemiaSamarpana Chakraborty, Claudia Morganti, Kimberly Zaldana, et al.
Blood|August 15, 2018
North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapiesUrvi A Shah, Elaine Y Chung, Orsi Giricz, et al.
The Journal of Clinical Investigation|September 26, 2018
Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cellsAditi Shastri, Gaurav Choudhary, Margarida Teixeira, et al.
Nature Communications|May 13, 2026
Chromatin rewiring of β-globin and MYC enhancers by TGF-β1 drives defective erythropoiesisSrinivas Aluri, Kimo Bachiashvili, Anjali Budhathoki, et al.
Cancer Discovery|October 1, 2025
Elevated Clonal Hematopoiesis in 9/11 First Responders Has Distinct Age-related Patterns and Relies on IL1RAP for Clonal ExpansionDivij Verma, Rachel Zeig-Owens, David G Goldfarb, et al.
Pageof 7